Table 3.
Incidence of SPMs at different anatomic sites in survivors of nasopharyngeal carcinoma
| Cancer type | No. of patients (%) |
|---|---|
| All | 189 (3.00) |
| Nasal | 7 (0.11) |
| Oral cavity | 34 (0.53) |
| Oropharynx | 7 (0.11) |
| Hypopharynx | 2 (0.03) |
| Larynx | 2 (0.03) |
| External auditory canal | 3 (0.05) |
| Lung | 50 (0.79) |
| Sarcoma | 9 (0.14) |
| Leukemia | 1 (0.02) |
| Multiple myeloma | 1 (0.02) |
| Lymphoma | 2 (0.03) |
| Thyroid | 12 (0.19) |
| Bladder | 2 (0.03) |
| Cervix | 2 (0.03) |
| Breast | 4 (0.06) |
| Skin | 5 (0.08) |
| Nerve | 1 (0.02) |
| Kidney | 3 (0.05) |
| Adrenal gland | 3 (0.05) |
| Esophagus | 3 (0.05) |
| Stomach | 7 (0.11) |
| Colorectal | 12 (0.19) |
| Liver | 15 (0.24) |
| Pancreas | 1 (0.02) |
| Bile duct | 1 (0.02) |
SPM, second primary malignancy.